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Persons with neurodevelopmental disorders or autism spectrum disorder (ASD) often harbor chromosomal microdeletions, yet the indi-
vidual genetic contributors within these regions have not been systematically evaluated. We established a consortium of clinical diag-
nostic and research laboratories to accumulate a large cohort with genetic alterations of chromosomal region 2q23.1 and acquired 65
subjects with microdeletion or translocation. We sequenced translocation breakpoints; aligned microdeletions to determine the critical
region; assessed effects on mRNA expression; and examined medical records, photos, and clinical evaluations. We identified a single
gene, methyl-CpG-binding domain 5 (MBD5), as the only locus that defined the critical region. Partial or complete deletion of MBD5
was associated with haploinsufficiency of mRNA expression, intellectual disability, epilepsy, and autistic features. Fourteen alterations,
including partial deletions of noncoding regions not typically captured or considered pathogenic by current diagnostic screening, dis-
ruptedMBD5 alone. Expression profiles and clinical characteristics were largely indistinguishable betweenMBD5-specific alteration and
deletion of the entire 2q23.1 interval. No copy-number alterations of MBD5 were observed in 7878 controls, suggesting MBD5 alter-
ations are highly penetrant. We surveyed MBD5 coding variations among 747 ASD subjects compared to 2043 non-ASD subjects
analyzed by whole-exome sequencing and detected an association with a highly conserved methyl-CpG-binding domain missense
variant, p.79Gly>Glu (c.236G>A) (p ¼ 0.012). These results suggest that genetic alterations ofMBD5 cause features of 2q23.1 microde-
letion syndrome and that this epigenetic regulator significantly contributes to ASD risk, warranting further consideration in research and
clinical diagnostic screening and highlighting the importance of chromatin remodeling in the etiology of these complex disorders.Introduction
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autosomal-dominant mental retardation type 1 (MRD1
[MIM 156200]). The region was initially identified in
2003 from one of the first comparative genomic hybridiza-
tion (CGH) surveys of developmental disorders,1 and 18
cases with the 2q23.1 microdeletion have since been
described; the phenotypic features include intellectual
disability, severe speech impairment, seizures, behavioral
problems, microcephaly, mild craniofacial dysmorphism,
small hands and feet, short stature, and broad-based ataxic
gait.1–9
Advances in the resolution of genomic microarray tech-
nology and the power of next-generation sequencing now
offer a route to more detailed definition of microdeletion
syndrome regions. In some cases, such as deletion 2q33.1
(SATB2 [MIM 608148]), deletion 22q13.3 (Phelan-McDer-
mid syndrome [MIM 606232]; SHANK3 [MIM 606230]),
deletion 13q12.3 (Peters Plus syndrome [MIM 261540];
and B3GALTL [MIM 610308]), and others,10–13 individual
genes have been implicated in generating the character-
istic phenotype. Such findings might signify an important
paradigm shift in the required resolution of diagnostic
assessment, because small gene-specific microdeletions
could result in a similar phenotype to that seen in the
larger deletion syndrome, suggesting that diagnostic arrays
should include not only coding regions but also noncod-
ing exons in the assessment, particularly for dosage-sensi-
tive genes. Consequently, we assembled a collaborative
team of clinical diagnostic laboratories and research
facilities in the United States, Canada, and Europe to
characterize the genetic content and phenotypic outcomes
associated with a spectrum of genetic alterations within
the 2q23.1 deletion syndrome region. We demonstrate
that MBD5 (MIM 611472), encoding the methyl-CpG-
binding domain 5 protein, is a clear causal locus within
the 2q23.1 deletion region and represents a previously
unrecognized contributor to the genetic etiology of autism
spectrum disorder (ASD).Material and Methods
Subjects
We established an international collaboration to identify a cohort
of individuals with deletion or translocation involving chromo-
some band 2q23.1 from chromosome analysis ormicroarray-based
CGH at referring centers and collaborating institutions. When
available, peripheral blood was collected, and DNA, RNA, and
lymphoblastoid cell lines were prepared according to standard
methods. Phenotypic information was obtained from diagnostic
referral data, medical records, clinical reports, genetics clinic eval-
uations, neurodevelopmental and/or psychological evaluations,
parent surveys, photos, previously published articles, and/or
a clinical checklist sent to the referring physician. All samples
and information were collected after informed consent was ob-
tained and in accordance with local institutional review board
approved protocols from Virginia Commonwealth University,
Harvard Medical School, Children’s Hospital of Boston, Case
Western Reserve University, Partners HealthCare System, Istituto
Di Ricovero e Cura a Carattere Scientifico (IRCCS) Associazione552 The American Journal of Human Genetics 89, 551–563, OctoberOasi Maria Santissima, or Radboud University Medical Centre. In
follow-up analyses, we sequenced 747 subjects whomet diagnostic
criteria for ASD from the Simon’s Simplex Collection and the
Autism Consortium of Boston. All subjects were assessed by
structured clinical interview with the Autism Diagnostic Inter-
view-Revised (ADI-R) or Autism Diagnostic Observation Schedule
(ADOS).14–16 We surveyed CNV and exome data from large collab-
orative studies as comparison groups. The CNV data were obtained
frommultiple data sets of the International Schizophrenia Consor-
tium (ISC). Rare CNVs were combined and cleaned to account for
time and technology used according to the same procedure
described previously.17–22 After filtering with a variant resolution
of >100 kb, 7878 controls remained in the data set. Exome-
sequencing data were obtained from the ongoing National Heart,
Lung, and Blood Institute (NHLBI) Grand Opportunity (GO)
Exome Sequencing Project (2043 individuals deeply phenotyped
for disorders of the heart, lungs, and blood were sequenced for
theMBD5 variant of interest). Data from this project were obtained
from the Exome Variant Server in July 2011 (see Web Resources).Phenotype Analysis
Data were collected for up to 70 characteristics related to subjects’
medical and developmental history and neurological, behavioral,
and physical characteristics (data not shown, Table 1). Short
stature was defined by clinicians as height less than the 5th percen-
tile or significantly shorter than siblings. Characteristics that were
age dependent (behavior, sleep patterns, and craniofacial and skel-
etal abnormalities) were scored accordingly on the basis of devel-
opment. Autistic-like symptoms were defined as either having re-
ported autistic-like behaviors or were specifically evaluated with
the ADOS, ADI-R, or given a diagnosis of Pervasive Developmental
Disorder (PDD-NOS). Eye abnormalities and outer ear abnormali-
ties varied among subjects and were grouped in the above broad
categories. Data were analyzed from 65 patients (males and
females). We compared 48 characteristics that were frequently
reported to be associated with 2q23.1 deletion syndrome in
51 individuals with 2q23.1 deletions to 14 individuals with partial
deletion and/or MBD5-specific alterations. All features were
compared and scored as present, absent, or data not available.
The frequency of each feature reflects the information reported
by specialists in this study.Genetic Studies
All subjects were analyzed for the purpose of clinical diagnostics
with different oligonucleotide or bacterial artificial chromosome
(BAC) array platforms available in academic or commercial
diagnostic laboratories. All genomic positions are provided for
human genome build NCBI36/hg18 because this was the common
reference from the clinical diagnostic laboratories (UCSC Genome
Browser, see Web Resources). Two translocation cases were ana-
lyzed by massively parallel paired-end sequencing on Illumina
sequencing platforms (Illumina). DNA from DGAP142 was previ-
ously sequenced by a DNA capture method (CapBP) on the basis
of cytogenetic analyses that had narrowed the breakpoint region
to <1 Mb.23 DNA from SMS373 was sequenced with a customized
whole-genome large insert jumping library. This method
sequences the ends of fragments that were manipulated by molec-
ular techniques to be separated by 3.5 kb inserts and yields very
high physical coverage of the genome by the inserts between
paired-end reads at minimal sequencing costs. In brief, 20 mg
of DNA was sheared by a Covaris S2 and size selected around7, 2011
3.5 kb. Cap adaptors with EcoP15I restriction sites were ligated to
the ends, and fragments were circularized with an internal oligo-
nucleotide adaptor containing a subject-specific barcode and
a single biotinylated thymine. Restriction enzyme digestion was
then performed, and biotinylated fragments containing the circu-
larization junction were bound to streptavidin beads followed by
standard library preparationwith NEBnext reagents (New England
Biolabs) and Illumina paired-end adaptors (see Talkowski et al.23
for a detailed description of all protocols and reagents).
To assess further the observed association between microdele-
tion of MBD5 (RefSeq NM_018328.4) and ASD, we performed
a low-cost, high-throughput pooled PCR next-generation
sequencing analysis of all MBD5 exons as previously described.24
In brief, we designed PCR amplicons spanning all coding and non-
coding MBD5 exons, and we designed primers with a NotI restric-
tion site (Table S1, available online). Samples were quantified by
PicoGreen (Quant-iT) and normalized to equimolar concentra-
tion. PCR amplification was then performed for all MBD5 exons
in all individuals and the products were again quantified by Pico-
Green and normalized. Failed PCRs were repeated. As described by
Calvo et al.,24 products were then concatemerized, size selected,
randomly sheared by a Covaris S2, and size selected again, fol-
lowed by Illumina paired-end library preparation of the sheared
products (Illumina). Pooled libraries were quantified by qPCR
with a serially diluted Illumina PhiX sample as a standard curve
and sequencing was performed on two lanes of an Illumina Hi-
Seq2000 with a targeted minimum read depth of 1003 per exonic
base (see Calvo et al.24 for complete details). The methodology
was designed to be sensitive to detect variants withmultiple occur-
rences in the case pools but was unlikely to have power to identify
mutations in a single individual, though one such variant
(p.1048Thr>Ile [c.3143C>T]) was discovered and validated.
Following analysis (see below), confirmatory genotyping of all
putative variants was performed with Sequenom iPLEX chemistry
(Sequenom) on the 600 individuals in the pooled sequencing anal-
ysis as well as 147 additional samples available from the same
resources (Simon’s Foundation and Autism Consortium of
Boston). To exclude any possible artifacts from pooled sequencing
and genotypes, all mutations validated by Sequenom were again
confirmed by capillary sequencing of both forward and reverse
strands in the ASD case, both parents, and any available siblings.
In all sequencing experiments (breakpoint detection or muta-
tion screening), reads were aligned with BWA25 or Novoalign (No-
vocraft). For translocations, BAM files were processed to identify
rearrangement breakpoints by a freely available Cþþ program,
BamStat (see Web Resources), developed to tabulate mapping
statistics and output lists of anomalous read-pairs (defined as
having ends thatmap to two different chromosomes, an abnormal
insert size, or unexpected strand orientations).23 Mutation anal-
ysis was performed with the Genome Analysis Toolkit26,27 and
Syzygy.28 Because the study design involved a case-only analysis,
no association tests were performed in Syzygy, instead Syzygy
was used exclusively to identify putative mutations for further
analysis.
Expression Analyses
Samples available for expression analyses are highlighted in green
in Figures 1 and 2. Lymphoblastoid cell lines (LCLs; human
lymphocytes transformed with Epstein-Barr virus) from 2q23.1
deletion syndrome patients and controls were cultured according
to standard methods. RNAwas isolated from LCLs or lymphocytes
collected from fresh blood and cDNA was prepared according toThe Americpublished methods.29 Quantitative RT-PCR was performed for
mRNA expression of MBD5 and EPC2 as previously described.2
Briefly, predesigned assays on Demand Gene Expression Products
(Fermentus, Glen Burnie, MD) Taqman minor groove binder
(MGB) probes forMBD5 and EPC2were used (Applied Biosystems).
GAPDH (MIM 138400) was used as the endogenous control. All
samples of cDNA were run in triplicate in 10 ml reaction volumes.
TaqmanUniversalPCRMasterMix (AppliedBiosystems), theprobe,
and deionized water were mixed together in a fixed ratio, and
diluted cDNA (1:5) was then added to each well. PCR conditions
were the Standard 7500 Run mode of the ABI Prism 7900 HT
Sequence Detection System (Applied Biosystems). Cycle threshold
(CT) was determined during the geometric phase of the PCR ampli-
fication plots, as recommended by the manufacturer. Relative
differences in transcript levels were quantified according to the
DDCt method and normalized to GAPDH. Acquired data were
analyzedwith 7500Fast SystemSDSSoftware (AppliedBiosystems).
Standard error was generated for each sample as previously
described, and significance (p < 0.05) was determined by a one-
sample t test compared to theoretical mean of 1.0 (p < 0.001 for
all deletion cases). Results are expressed as fold-change relative to
1.0 (normal control). EPC2 expression was evaluated to rule out
positional effects because of singular deletion ofMBD5 (Figure S1).
Statistical Analyses
For the phenotype data, comparison of proportions in two-way
contingency tables was performed with the Fisher’s exact test as
previously described.30,31 All reported p values are two-tailed.
Given the known correlation between clinical variables, it is
often difficult to assess the true number of independent tests per-
formed. Though conservative, we performed Bonferroni correc-
tion for all pair-wise comparisons (Table 1). Statistical analysis
for gene-expression data was performed with Prism 4 version
4.0b (GraphPad Software). A simple Fisher’s exact test for allelic
association was performed for the lone mutation tested.Results
Analyses presented here sought to characterize genetic and
phenotypic heterogeneity associated with the 2q23.1 mi-
crodeletion syndrome region and particularly to determine
whether one gene or multiple genes in the region
contribute to the abnormal phenotypes. Our analyses
progressively focused on a single gene, MBD5, which we
implicated as a single causal locus for the bulk of the char-
acteristic phenotypic manifestations of the 2q23.1 micro-
deletion syndrome.
Refinement of the 2q23.1 Deletion Syndrome Critical
Region
We identified 65 cases, including the 19 previously re-
ported cases and 46 new cases, with microdeletions or
translocation of 2q23.1 ranging from small deletions of
38 kb to >19 Mb, (Figure 1). Remarkably, after aligning
the deletion regions, the smallest region of overlap (SRO)
was defined to one gene, MBD5, that was within 2q23.1
and was common in all deletions and disrupted in both
translocations (Figure 1). No other genes were included
in the SRO for all deletions or were present in deletionsan Journal of Human Genetics 89, 551–563, October 7, 2011 553
Table 1. Phenotypic Comparison of MBD5 Alterations and 2q23.1 Deletions
Common Features
MBD5-Specific Disruption 2q23.1 Deletion
p ValueaFrequency Percentage Frequency Percentage
Neurological and/or behavioral
Developmental delay 14/14 100 51/51 100 1
Motor delay 6/6 100 25/25 100 1
Language impairment 5/7 71.4 24/24 100 0.427
Ataxia 0/3 0 15/21 71.4 0.042
Infantile hypotonia 3/4 75.0 14/15 93.3 0.386
Infantile feeding difficulties 2/3 66.6 14/14 100 1
Seizures 6/7 85.7 22/27 81.5 1
Behavioral problems 7/7 100.0 24/24 100 1
Sleep disturbances 3/6 50 11/15 73.3 0.354
Short attention span 4/4 100 11/11 100 1
Self-injurious behavior 1/3 50.0 14/23 60.8 1
Stereotypic repetitive behavior 3/5 60.0 15/17 88.2 0.210
Aggression 1/2 50 6/6 100 1
Hyperphagia 0/4 0 7/9 77.8 0.021
Autistic-like symptoms 14/14 100 51/51 100 1
Growth abnormalities
Postnatal growth retardation 2/5 40.0 21/23 91.3 0.027
Short stature 2/5 40.0 19/22 86.4 0.056
Craniofacial abnormalities
Craniofacial manifestations 4/6 66.6 26/26 100 0.030
Microcephaly 0/5 0 18/20 90.0 0.004
Brachycephaly 0/5 0 8/22 36.4 0.280
Broad forehead 2/5 40.0 14/16 87.5 0.063
Synophrys 1/5 20.0 8/17 47.1 0.360
Thick/arched eyebrows 1/1 100 15/20 75.0 1
Eye abnormalities 3/5 60.0 11/15 73.3 0.621
Hypotelorism 0/5 0 7/21 33.0 0.278
Midface retrusion (hypoplasia) 1/6 16.6 9/18 50.0 0.341
Nasal abnormalities 4/4 100 25/25 100 1
Outer ear abnormalities 2/5 20.0 14/16 87.5 0.025
Wide mouth 0/5 0 12/15 80.0 0.037
Open mouth 2/6 33.3 20/22 90.9 0.010
Vermillion, thin upper lip 2/2 100 15/20 75.0 1
Vermillion, tented upper lip 1/5 20.0 13/20 65.0 0.133
Thick or everted lower lip 1/3 33.3 12/18 66.6 0.530
Downturned corners of the mouth 0/3 0 13/18 72.2 0.042
Dental abnormalities 3/6 50.0 11/21 52.3 1
Widely-spaced teeth 1/2 50.0 8/17 47.1 1
Large tongue, macroglossia 0/5 0 4/21 19.0 0.552
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Table 1. Continued
Common Features
MBD5-Specific Disruption 2q23.1 Deletion
p ValueaFrequency Percentage Frequency Percentage
Short chin/micrognathia/retrognathia 3/5 60.0 12/20 60.0 1
Skeletal abnormalities
Hand/foot anomalies 4/6 66.6 23/24 95.8 0.094
Small hands and feet 1/5 20.0 18/24 75.0 0.036
Clinodactyly, 5th finger 1/5 20.0 15/22 68.2 1
Brachydactyly 0/4 0 9/22 40.9 0.263
Short fifth digit of hands/feet 0/4 0 7/17 41.2 0.090
Sandal gap 3/6 50 5/20 25.0 0.330
Other Abnormalities
Cardiovascular abnormalities 0/5 0 2/18 11.1 1
Urogenital abnormalities 0/4 0 6/21 28.6 0.540
Constipation 5/5 100 9/10 90 1
Localized hirsutism 0/5 0 4/18 22.2 0.539
a Uncorrected p value from Fisher’s exact test. No results were significant following Bonferroni correction for multiple testing.that did not also involveMBD5. Fourteen (21.5%) of the 65
microdeletions and translocations were exclusively local-
ized to the MBD5 locus, including several deletions that
did not alter the MBD5 protein coding sequence because
they were restricted to portions of the large noncoding
region that contains multiple exons 50 to the exon 6 trans-
lational start site (Figure 2, top).
The breakpoint capture sequencing previously per-
formed for DGAP142, 46,XY,t(2;22)(q23.1;q13.31), identi-
fied a near perfectly balanced translocation between the
long arms of chromosomes 2 and 22 that directly disrupted
the 50-noncoding region of MBD5 and did not impact any
annotated genes, functional elements, or conserved
sequences on 22q (Figure 2, bottom). Whole-genome
sequencing of SMS373, 46,XY,t(2;10)(q23.1;q25.3), re-
vealed an unbalanced translocation between the long
arms of chromosomes 2 and 10 that also directly disrupted
the 50-noncoding region ofMBD5 (Figure 2, bottom). Dele-
tions were detected at the breakpoints of both chromo-
some partners; a 192,277 bp loss at the MBD5 breakpoint
with insertion of 7 bp of foreign sequence that could not
be uniquely aligned elsewhere in the genome (Figure 2,
bottom) and a 106,412 bp deletion on chromosome 10
that included disruption of attractin-like 1 (ATRNL1 [MIM
612869]). Breakpoints in both cases were confirmed by
PCR and Sanger sequencing.
Phenotype Analysis Indicates that Most Features of
2q23.1 Deletion Syndrome Are Associated withMBD5
Given thepower of our sample and the commondeletionof
MBD5 in all cases (Figure 1), wewere able to conduct amore
comprehensive clinical characterization of 2q23.1 micro-The Americdeletion syndrome, comparing 48 characteristic pheno-
types between individuals with MBD5-specific deletions
and those with broader 2q23.1 deletions to discriminate
those phenotypes associated exclusively with MBD5 dele-
tion (Table 1 and Figure 3). Results indicate that most
(39/48 ¼ 81.2%) phenotypic features of 2q23.1 deletion
syndrome are consistent between both MBD5-specific
alterations and larger 2q23.1 deletions. The frequently
reported neurological, neurobehavioral, and craniofacial
features associated with this syndrome were collectively
observed in both cohorts. We report 13 out of 15 specific
neurological and/or neurobehavioral features that were
not significantly different between2q23.1 deletion subjects
andMBD5-specific disruption subjects, including develop-
mental delay, motor delay, seizures, language impairment,
and various behavioral problems (Table 1). In previous liter-
ature on 2q23.1, seizures and severe language impairment
emerged as the two primary features associated with this
disorder. In our assessment of severe language impairment
in both cohorts, it is apparent that this feature is a common
finding; 100%of 2q23.1 deletion cases and71.4%ofMBD5-
specific disruption cases exhibit this phenotype. Seizures
were also commonly reported in both groups at rates
greater than >80%. We also set apart several craniofacial
features, including thickor arched eyebrows, eye abnormal-
ities, nasal abnormalities, thin upper lip, widely spaced
teeth, and small chin, micrognathia, or retrognathia,
present in statistically similar frequencies in both cohorts
(Table 1). In addition, eye abnormalities that included eso-
tropia, myopia, astigmatism, hypermetropia, and poor
vision were observed in both cohorts. Individuals in both
cohorts also exhibited either large prominent noses (olderan Journal of Human Genetics 89, 551–563, October 7, 2011 555
Figure 1. Delineation of the 2q23.1 Critical Region
Schematic representation ofMBD5-containing deletions and translocation breakpoints in this report and those previously reported in the
literature, arranged from largest to smallest. Boxes represent the minimum size of the deletions, and the horizontal lines extend through
gaps in coverage to show the maximum deletion sizes. Green boxes represent individuals withMBD5 expression studies reported here.
Single asterisks indicate cases known to be de novo; a double asterisk indicates a single inherited case in the cohort. Inheritance regarding
all other cases is unknown. Genes within the region are represented by blue boxes, and the shaded region shows the location ofMBD5.individuals) or small bulbous shaped noses (younger indi-
viduals) (see Figure 3). Note the thin upper lip observed in
all 2q23.1 deletion subjects (Figure 3).556 The American Journal of Human Genetics 89, 551–563, OctoberAlthough it is apparent that amajority of theneurological
and neurobehavioral features were consistent among
2q23.1 deletion and MBD5-specific disruption cases, key7, 2011
Figure 2. Deletions and Translocations Disrupting MBD5
(Top) Schematic representation of intragenic and partial deletions of MBD5.MBD5 genomic organization andmRNA (RefSeq Accession:
NM_018328) are provided, including the large noncoding region (in green) between exon 1 and the coding sequence start site (in blue).
Above the gene are the 18microdeletions that partially and/or exclusively disruptMBD5. These subjects had similar phenotypic features
to individuals with deletions of the full 2q23.1 region (Table 1). Green bars represent those cases with expression data shown in Figure 4.
Single asterisks indicate cases known to be de novo; the double asterisk indicates a single inherited case in the cohort. Inheritance
regarding all other cases is unknown.
(Bottom) Translocation breakpoints inMBD5. Below the gene are paired-end sequencing data from two translocations found to disrupt
MBD5. The arrows represent the orientation of sequence reads (inward facing for CapBP, outward facing for jumping libraries). The
breakpoint on chromosome 2 in SMS373 was localized to the MBD5 noncoding region but determined to be an unbalanced rearrange-
ment with derivative breakpoints separated by 193 kb on chromosome 2 and 106 kb on chromosome 10. DGAP142 yielded read pairs
that localized the junction fragment to the same noncoding region23 with the loss of a single base at the chromosome 22 breakpoint in a
region without annotated genes or functional sequences. Breakpoint sequences are given below the reads. The blue sequence represents
the chromosome 2 breakpoint; the red sequence represents the chromosomal partner sequence, and the sequence at the breakpoint
that does not map to either chromosome partner is inserted in gray. Breakpoints for both derivatives resulting in the 193 kb deletion
of chromosome 2 are shown for SMS373. The second derivative of DGAP142 was balanced and identical to the reference.differences exist between the two cohorts; these include the
presence in the 2q23.1 deletion cohort of ataxia, hyper-
phagia, postnatal growth retardation, a variety of craniofa-
cial manifestations, and small hands and feet (Table 1).
Hyperphagia is observed in 2q23.1 deletion cases (77.8%)
and is not reported in any of theMBD5-specific disruptions
(0%) (p ¼ 0.021). Craniofacial manifestations overall also
appear to be more frequent in 2q23.1 deletion patients
(100%) than in MBD5-specific disruptions (71.4%) (p ¼
0.030). Specifically, five distinct craniofacial manifesta-
tions, microcephaly, external ear abnormalities, wide
mouth, open mouth, and downturned corners of the
mouth, appeared more commonly in 2q23.1 deletion sub-
jects compared toMBD5-specific disruption subjects (Table
1), suggesting other genes could be involved in the etiology
of these features. Further, external ear abnormalities such as
prominent ears, small ears with large lobules, large simple
cupped ears, low-set ears, or abnormal ears were observed
at a higher frequency in patients with 2q23.1 deletionsThe Americthan in MBD5-specific disruptions (Table 1). The single
feature that is significantly more prevalent in the 2q23.1
deletion cohort (75%) than in theMBD5-specific disruption
cohort (20%) is small hands and feet (p ¼ 0.036).
No patients with MBD5-specific disruptions were
described as having brachycephaly, hypertelorism, macro-
glossia, short fifth digit of hand or feet, cardiovascular
abnormalities, urogenital abnormalities, or localized
hirsutism; however, the tests lack power because of the
low number of cases observed. Some unique features that
are reported in a few of the 2q23.1 deletion subjects are
a high, narrow palate (5), genital abnormalities (5), a lower
anterior hairline (4), pes planovalgus (3), long palpebral
fissures (3) and mild metopic ridging (2).
Haploinsufficiency of MBD5
Prior to this study, we established haploinsufficiency of
MBD5 in two larger 2q23.1 deletion cases (individuals
SMS185 and SMS361);2 however, those cases had deletionsan Journal of Human Genetics 89, 551–563, October 7, 2011 557
Figure 3. Clinical Features of Patients with Haploinsufficiency of MBD5
(A–D) The individuals presented have different 2q23.1 deletions (Figure 1). (A) SMS375, age 19 months. Note the microcephaly
(45.8 cm, < 3rd percentile), broad forehead, bulbous nose, simple protruding ear lobes, and thin upper lip. (B) SMS373, age 2. Note
the broad forehead, midface hypoplasia, high and broad nasal root, bulbous nose, fleshy ear lobes with bilateral Darwinian tubercle,
and thin upper lip. (C) SMS367, age 7. Note low anterior hairline,midface retrusion (hypoplasia), large pronounced nose, and prominent
columella. Note the space between the incisors. (D) SMS368, age 20. Note the bitemporal narrowing, synophrys, large pronounced nose,
prominent ears, prominent columella, protruding upper teeth, and short neck.
(E) Hands of SMS373. Note the small plump hands, brachydactyly, and fifth finger clinodactyly.
(F) Feet of SMS373. Note the small feet and sandal gap between first and second toes.
(G) Feet of SMS368 illustrating small size and slight sandal gap between first and second toes.
(H) Hands of SMS368. Note the small hands with tapered fingers and the fifth finger clinodactyly.involving other genes and also exhibited haploinsuffi-
ciency of EPC2 (Figure 1). Here, we assessed the impact
of MBD5 promoter, 50-noncoding exon, or coding exon
deletions in 2q23.1 deletion subjects on MBD5 expression
(Figure 4). We discovered that MBD5 mRNA expression
levels were significantly reduced (22.5%–55.4%; p <
0.0001) across all 2q23.1 deletions studied when compared
with the levels in normal controls (Figure 4). Because Wil-
liams et al.2 reported that EPC2 was haploinsufficient in
the two large deletion cases, we also studied EPC2 mRNA
levels in cell lines with MBD5-specific intragenic deletions
and found normal levels of expression, indicating absence
of positional effects from these events on EPC2 expression
compared to controls (Figure S1). These data support
haploinsufficiency of MBD5 as the only shared etiological
finding among all cases evaluated, including those with
alterations affecting the 50-noncoding regions of the gene.
Association of MBD5 with Autism
The genetic and phenotypic analyses suggested that the
majority of 2q23.1 deletion cases exhibited autistic-like
behaviors, some of which were referred with a clinical indi-
cation of ASD. As MBD5 has not been implicated previ-
ously in autism, we explored this hypothesis further. We
estimated the frequency of the MBD5 microdeletion in
ASD from a subset of the total clinical data for which we
had clear evidence of the total number of subjects with558 The American Journal of Human Genetics 89, 551–563, OctoberASD. From the Children’s Hospital Boston data set, we
identified three independent microdeletions in cases
with ASD (a fourth case was a sibling who also carried
the same microdeletion) from a total sample of 1786 ASD
subjects (0.17%), and from a subset of the Signature Geno-
mics data set with definitive phenotypic information and
identical diagnostic array data, we observed a highly
similar rate of four microdeletions of MBD5 from 2275
ASD cases (0.18%). A comparison to the 7878 controls
screened for absence of psychiatric diagnosis found no
deletions of the 2q23.1 segment, the full MBD5 locus, or
any MBD5 coding exons, suggesting that haploinsuffi-
ciency of MBD5 is highly penetrant. A survey of the Data-
base of Genomic Variants (DGV) found a very large dupli-
cation spanningmany genes in the region but no deletions
greater than 3 kb, all of which were confined to intronic
sequences in the 50-noncoding region.
Pooled sequencing of the MBD5 coding region and
confirmatory individual sample genotyping in 747 cases
diagnosed with ASD identified a previously described
missense variant in the highly conserved and functionally
critical methyl-binding domain (MBD), p.79Gly>Glu
(rs34995577). Capillary sequencing confirmed an inherited
mutation in six ASD cases (0.8% heterozygote frequency;
0.4% minor allele frequency; four of maternal inheri-
tance, two of paternal inheritance). A second variant,
p.1048Thr>Ile, was confirmed to be inherited in a single7, 2011
Figure 4. Reduced MBD5 Expression with
MBD5 Deletions or Disruptions
Quantitative RT-PCR mRNA expression analysis
of MBD5 is shown in lymphoblastoid cell lines
or peripheral blood lymphocytes from individ-
uals with MBD5 deletions (partial or complete)
or disruptions of MBD5 and nine unaffected (no
MBD5 deletion) subjects that were used as normal
controls. Results were normalized to GAPDH
expression. Relative expression values are based
on the DDCt value. Expression of all controls
was normalized to one. Each bar represents
mean (5standard error of the mean) of values
from three to ten independent experiments.
The error bars are present for each sample, but
in some cases the error bars are too small to be seen. The data show a normal range of expression, 0.94- to 1.23-fold MBD5 expression,
in lymphocytes (BC1-2) and lymphoblastoid cell lines (LCL1-7). Samples from cases described herein show 22%–55% expression of
MBD5 (p < 0.0001 for all cases). aSMS185 and SMS361 were previously reported.2ASD case, but no other variants were observed more than
once. The frequency of the p.79Gly>Glu variant in ASD
subjects was significantly higher than the minor allele
frequency in the ESP exome sequencing (3/2043 individ-
uals sequenced, MAF ¼ 0.07%), suggesting increased risk
conferred to ASD cases by the mutant allele (p ¼ 0.012,
OR ¼ 5.47, 95% confidence interval ¼ 1.37–21.9). The
G79 residue is conserved in human and mouse and highly
conserved across MBD proteins, including MECP2 (MIM
300005), MBD1 (MIM 156535), MBD2 (MIM 603547),
and MBD3 (MIM 603573).Discussion
Our large-scale characterization of a microdeletion
syndrome previously implicated in neurodevelopmental
abnormalities revealed that a spectrum of genetic alter-
ations results in highly similar phenotypic presentations,
including small alterations localized to noncoding ge-
nomic regions. We identified 65 structural rearrangements
spanning the 2q23.1 region, all of which disrupted a single
gene in the critical region, MBD5, and included 14 inde-
pendent structural variants (SVs) that solely interrupt
MBD5. Extensive analysis of phenotypic features shows
that partial or complete deletion of MBD5 leads to the
core phenotype of intellectual disability, seizures, signifi-
cant speech impairment, and behavioral problems
observed in 2q23.1 deletion syndrome. Haploinsufficiency
of MBD5 mRNA, including deletions of only the 50-non-
coding region, was confirmed in all cases evaluated and
supports MBD5 as the major causative gene for 2q23.1
deletion syndrome and the core phenotype observed.
Many of the 2q23.1 deletion cases exhibited ASD features,
and we empirically estimated the frequency of MBD5 mi-
crodeletion and mutation of a highly conserved domain
in MBD5 in ASD cases as well as comparison groups
without ASD and found substantial risk conferred by
MBD5 alteration. Our best estimates are that MBD5 dele-
tion could impact one out of 500 to one out of 1000 ASD
cases, and collectively, we find that up to 1% of ASD casesThe Americcould have an alteration ofMBD5 that confers genetic risk
on the basis of the samples studied here.
MBD5 encodes a protein of the methyl-CpG-binding
domain (MBD) family that also includes MECP2, a causa-
tive locus in Rett syndrome (RTT [MIM 312750])32 and
is highly expressed in the brain, fetal testes, and fetal
ovaries.32 As a member of the MBD protein family, the
MBD5 protein has a 71 amino acid MBD from positions
11–81 of the protein. The p.79Gly>Glu variant, which is
overrepresented in ASD in our study, changes amino acid
79 in the MBD from glycine to glutamate and is predicted
by PolyPhen-2 (score ¼ 0.995)33 to be damaging to the
function of this highly conserved domain known to be
involved in binding DNA at methylated CpGs. Specific
cellular functions of other MBD family members have
been well-described, but the function of MBD5 is currently
not understood. A recent study suggested that MBD5 is
unlikely to bind directly to methylated DNA but could
contribute to the formation or function of heterochro-
matin.32 MBD5 could bind to DNA in a complex because
it has been shown to interact directly with myocyte
enhancer-binding factor 2C,34 encoded by MEF2C (MIM
600662), a gene known to play a crucial role in develop-
ment and neurogenesis35 and to regulate expression of
neuronal genes involved in formation of neuronal circuits
and synaptic functions.10 Haploinsufficiency of MEF2C is
associated with a microdeletion in 5q14.3 that results in
an ASD phenotype, intellectual disability, seizures, and
hypotonia,36 strikingly similar to the phenotype described
here for haploinsufficiency of MBD5. Thus, MBD5 and
MEF2C might function in a common pathway in neuro-
genesis, which, when disrupted, reveals characteristic neu-
rodevelopmental phenotypes.
This analysis is the first comparative clinical study of
this magnitude to define the role of a single gene in the
clinical manifestations of 2q23.1 microdeletion syndrome
and ASD and/or autism. Overall, ~84% of phenotypic
features evaluated were consistently observed in both
MBD5-specific deletion and 2q23.1 deletion cases, suggest-
ing that the overall syndrome phenotype is primarily due
to MBD5 deletion. Developmental delay, motor delay,an Journal of Human Genetics 89, 551–563, October 7, 2011 559
language impairment, seizures, behavioral problems,
several craniofacial manifestations (see Table 1), and con-
stipation were present in all or a majority ofMBD5-specific
disruptions and 2q23.1 deletions involving MBD5, sup-
porting a significant role for MBD5 in these features. We
also report that, unlike larger 2q23.1 deletion cases,
MBD5-specific disruptions did not show microcephaly,
certain neurological, growth, and craniofacial manifesta-
tions, or small hands and feet (Table 1). These findings
suggest that altered gene dosage of other 2q23.1 genes
probably modifies and contributes to the variable features
in 2q23.1 deletion syndrome.
Our study specifically supports a role for MBD5 in ASD.
Data from numerous autism CNV studies suggest that
genetic etiology in at least 10% of autism patients can be
attributed to genetic syndromes and known chromosomal
anomalies, and estimates will increase as the resolution of
screening tools improves.37 Further, both deletions and
duplications, particularly involving chromosomal regions
16p13.11, 15q13.3, and 15q11.2, have been productive
in identifying genomic architectural changes that are
clearly associated with epilepsy and other developmental
conditions; there are similar findings in both autism and
schizophrenia cohorts, demonstrating enrichment of
these and other copy-number regions compared to appro-
priate controls.38–41 Because ~5%–15% of neurodevelop-
mental disorders, such as fragile X syndrome (MIM
300624; FMR1 [MIM 309550]), RTT (MECP2), Angelman
syndrome (MIM 105830; UBE3A [MIM 601623]), Smith-
Magenis syndrome (MIM 182290; RAI1 [MIM 607642])
and Potocki-Lupski syndrome (MIM 601883; RAI1),
tuberous sclerosis complex (MIM 191100; 613254; TSC1
[MIM 605284], TSC2 [MIM 191092]), neurofibromatosis
type 1 (MIM 162200; NF1 [MIM 613113]), and PTEN ha-
martoma syndrome (PTEN [MIM 601728]),42,43 are associ-
ated with a high prevalence of autism and are caused by
single genes, they can offer tremendous insight into the
pathogenesis of autism through the investigation of
protein and gene pathway interactions. Adding MBD5 to
the list of highly penetrant single genes that can
contribute to ASD provides additional support for genes
important in DNAmethylation and chromatin remodeling
in autism etiology. Other members of the MBD protein
family have also been implicated in ASD and/or autism,
most particularly MECP2, whose mutation or deletion
can lead to RTT, seizures, intellectual disabilities, and/or
autism.44,45 In support of these findings, existing mouse
models for inactivation of many of the MBD family genes
display autistic-like behavioral phenotypes that could be
valuable for investigating the pathophysiology of autism-
predisposing mutations and for identifying treat-
ments.45,46 The data presented here further support a role
for the MBD family in the etiology of ASD.
These analyses could represent a lower limit for the over-
all involvement ofMBD5 in ASD because clinical data were
limited for many individuals with detected microdele-
tions, the array resolution was too low on some platforms560 The American Journal of Human Genetics 89, 551–563, Octoberto adequately detect small alterations, and our sequencing
screen for mutation was limited to alleles observed
multiple times in the patient pools, meaning it was insen-
sitive to any potential accumulation of single private
mutations at a higher burden than in controls. The com-
parison of our data set to the available controls suggests
large deletions of MBD5 are highly deleterious and pene-
trant, as no variations were observed from 7878 controls.
Notably, the resolution of the CNV calls from the microar-
ray studies was low, and only variants >100 kb could be
confidently called. A higher resolution analysis could
reveal smaller variants in controls, such as those seen in
the 50-noncoding region of the gene from DGV, which
are intronic and less than 3 kb in size. Similarly, the
p.79Gly>Glu variant is present in control populations at
a significantly lower frequency than our cases. These data
could suggest amixedmodel of deleterious, fully penetrant
deletions of MBD5 causing the syndromic disorder
described here and reduced penetrance variants that signif-
icantly increase risk for ASD. A critical assessment of the
allele frequency reported in additional ASD subjects and
yet more controls will be required to determine the true
effect size of the association reported here, which was
limited to a relatively modest ASD cohort, but all variants
were confirmed by multiple methods including capillary
sequencing. It will also be of interest to evaluate ongoing
autism exome sequencing to determine the total spectrum
of MBD5 coding mutation burden, including those rare
events that our methods were insensitive to detect, and to
perform haplotype analyses of the region to determine if
associated mutations are recurrent or identical by descent
in the patient populations such as for the p.79Gly>Glu
variant. Importantly, our clinical detection of ASD cases
with these small alterations in the noncoding regions of
MBD5 points to the need for greater sensitivity and analysis
of current clinical diagnostic screening and proposes an
alternative to the yet unexplained heritability in ASD
from studies targeting large dosage changes or strictly de
novo mutations identified from exome sequencing.
Our large-scale characterization of a microdeletion
syndrome previously implicated in neurodevelopmental
abnormalities reveals that a complex spectrum of genetic
alterations, from point mutations and small deletions in
noncoding regions through to larger chromosomal rear-
rangements, can result in highly similar phenotypic
presentations, including ASD, because of effects on the
same critical gene. These results suggest that the impact
of both gross and quite subtlemutations at select loci could
account for a significant portion of the overall disease risk
in ASD and other neurodevelopmental disorders and that
microdeletion syndrome regions provide a potential route
to identifying these loci. Given similar findings supporting
the importance of single genes in smaller studies of
other recurrent microdeletion syndromes,10,12,47,48 small
gene-specific SVs can result in a similar phenotype to that
seen in the larger deletion syndrome. In addition to
revealing the need for specific consideration of MBD5 in7, 2011
the molecular diagnosis of certain neurodevelopmental
disorders, including ASD, our findings argue strongly for
similar collaborative experimental approaches to screening
of additional microdeletion syndromes for specific genetic
factors contributing to neurodevelopmental abnormalities.Supplemental Data
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